JP2016502526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502526A5 JP2016502526A5 JP2015542769A JP2015542769A JP2016502526A5 JP 2016502526 A5 JP2016502526 A5 JP 2016502526A5 JP 2015542769 A JP2015542769 A JP 2015542769A JP 2015542769 A JP2015542769 A JP 2015542769A JP 2016502526 A5 JP2016502526 A5 JP 2016502526A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- binding antibody
- composition according
- subject
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727334P | 2012-11-16 | 2012-11-16 | |
| US61/727,334 | 2012-11-16 | ||
| PCT/US2013/070042 WO2014078502A1 (en) | 2012-11-16 | 2013-11-14 | Use of il-1 beta binding antibodies for treating peripheral arterial disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016502526A JP2016502526A (ja) | 2016-01-28 |
| JP2016502526A5 true JP2016502526A5 (enExample) | 2016-12-28 |
Family
ID=49679654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542769A Pending JP2016502526A (ja) | 2012-11-16 | 2013-11-14 | 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10000565B2 (enExample) |
| EP (1) | EP2919811B1 (enExample) |
| JP (1) | JP2016502526A (enExample) |
| AU (1) | AU2013344796B2 (enExample) |
| CA (1) | CA2891556A1 (enExample) |
| WO (1) | WO2014078502A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180291097A1 (en) * | 2015-06-04 | 2018-10-11 | Craig Basson | Use of il-1 beta binding antibodies to treat peripheral arterial disease |
| JP2018516931A (ja) | 2015-06-04 | 2018-06-28 | ノバルティス アーゲー | 末梢動脈疾患を処置するためのｉｌ−１ベータ結合抗体の使用 |
| TWI833685B (zh) | 2015-07-31 | 2024-03-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 預測抗體之生物利用度之方法 |
| CN108603188A (zh) * | 2015-11-24 | 2018-09-28 | 联邦科学技术研究组织 | 在细胞培养物中产生病毒 |
| EP3487584A1 (en) * | 2016-07-21 | 2019-05-29 | Novartis AG | Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis |
| CA3045944A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20200315540A1 (en) | 2016-12-14 | 2020-10-08 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
| RU2020113234A (ru) * | 2017-09-13 | 2021-10-13 | Новартис Аг | ПРИМЕНЕНИЕ АНТИТЕЛ, СВЯЗЫВАЮЩИХ IL-1β, ДЛЯ ЛЕЧЕНИЯ АЛКОГОЛЬНОГО ГЕПАТИТА |
| EP3852617B1 (en) * | 2018-09-20 | 2025-09-10 | SFJ Pharma X, Inc. | Use of antibody fragments for reversing ticagrelor activity |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN112402359A (zh) * | 2020-11-04 | 2021-02-26 | 深圳前海鹰岗生物科技有限公司 | 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法 |
| WO2026006472A2 (en) | 2024-06-25 | 2026-01-02 | Kiniksa Pharmaceuticals, Gmbh | Compositions of il-1r1 antibodies and methods of producing and using the same |
| WO2026003765A1 (en) | 2024-06-25 | 2026-01-02 | Kiniksa Pharmaceuticals, Gmbh | Formulations of anti-interleukin 1 receptor 1 antibodies |
| WO2026145640A1 (zh) * | 2025-01-03 | 2026-07-09 | 长春金赛药业有限责任公司 | 一种抗IL-1β抗体的药物组合物及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| WO2008077145A2 (en) * | 2006-12-20 | 2008-06-26 | Xoma Technology Ltd. | Treatment of il-1-beta related diseases |
| WO2009120307A2 (en) | 2008-03-26 | 2009-10-01 | Orthologic Corp. | Method of treating peripheral arterial disease |
| KR20110016959A (ko) * | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| EP2297209A4 (en) * | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| AU2009289547A1 (en) * | 2008-09-05 | 2010-03-11 | Xoma (Us) Llc | Methods for treating or preventing IL-1beta related diseases |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| NZ593905A (en) * | 2009-01-29 | 2013-03-28 | Abbott Lab | Il-1 binding proteins |
| SG2014014534A (en) * | 2009-05-29 | 2014-07-30 | Xoma Technology Ltd | CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF |
| AU2010306681A1 (en) | 2009-10-15 | 2012-04-19 | Abbvie Inc. | IL-1 binding proteins |
| KR20130100118A (ko) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| WO2013049278A1 (en) * | 2011-09-30 | 2013-04-04 | Novartis Ag | USE OF IL-1 ß BINDING ANTIBODIES |
-
2013
- 2013-11-14 US US14/442,536 patent/US10000565B2/en not_active Expired - Fee Related
- 2013-11-14 JP JP2015542769A patent/JP2016502526A/ja active Pending
- 2013-11-14 AU AU2013344796A patent/AU2013344796B2/en not_active Ceased
- 2013-11-14 CA CA2891556A patent/CA2891556A1/en not_active Abandoned
- 2013-11-14 EP EP13798486.0A patent/EP2919811B1/en not_active Not-in-force
- 2013-11-14 WO PCT/US2013/070042 patent/WO2014078502A1/en not_active Ceased
-
2018
- 2018-05-21 US US15/984,993 patent/US20180258166A1/en not_active Abandoned
-
2019
- 2019-06-21 US US16/448,341 patent/US20200148759A1/en not_active Abandoned
-
2021
- 2021-04-15 US US17/231,400 patent/US20210317202A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102446673B1 (ko) | 암 치료를 위한 약물의 제조에 있어서 항-pd-1 항체 및 vegfr 억제제의 조합의 용도 | |
| Accardi et al. | Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma‐induced alterations of bone remodeling | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP5417653B2 (ja) | 抗−４−１ｂｂ抗体及び化学抗癌剤を含む癌疾患の予防及び治療用調合薬学的組成物 | |
| JP2015187125A5 (enExample) | ||
| JP2015530867A5 (enExample) | ||
| JP2017537105A5 (enExample) | ||
| KR20180018695A (ko) | 항암제 | |
| RU2471483C2 (ru) | Противоопухолевые комбинации, содержащие ингибитор vegf и иринотекан | |
| CA3043700A1 (en) | Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease | |
| US20240173403A1 (en) | Combination of AXL Antibodies and ACE Inhibitors in the Treatment of Fibrosis | |
| JP2013506684A5 (enExample) | ||
| JP2019533715A5 (enExample) | ||
| JP2016502526A (ja) | 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用 | |
| JP2016537380A5 (enExample) | ||
| KR20240090993A (ko) | 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체 | |
| Frappaz et al. | Phase 1 study of dalotuzumab monotherapy and ridaforolimus–dalotuzumab combination therapy in paediatric patients with advanced solid tumours | |
| AU2019392742A1 (en) | Anti-cancer activity of adamantane derivatives | |
| Topal et al. | Scleroderma therapy: clinical overview of current trends and future perspective | |
| CN119894507A (zh) | 嵌合抗原受体（car）t细胞辅助疗法 | |
| JP2018516931A5 (enExample) | ||
| RU2018114457A (ru) | Лечение syd985 пациентов с t-dm1 рефрактерным раком | |
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| JP2018537522A (ja) | 組合せ | |
| CA3118690A1 (en) | Use of tivozanib to treat subjects with refractory cancer |